
The Pharmalot View
Most Read


Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results

Azar has a ‘tin ear’ when it comes to pricing a potential coronavirus treatment

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

Kapoor certainly deserves to go to jail, but so do some other pharma execs

If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

Memo to the Novartis CEO: When in doubt, give the FDA a heads-up
